Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Baltimore Inner Harbor

Apr 05, 2027 8:00 AM - Apr 07, 2027 12:30 PM

401 W Pratt Street, Baltimore, MD 21201, USA

Global Pharmacovigilance and Risk Management Strategies Conference

Early Bird Rate Ends

DAYS

HOURS

MINUTES

SECONDS

Session 8: FDA’s New IND Safety Reporting Guidance and What It Means for Sponsors Today

Session Chair(s)

Scott  Janiczak, PharmD, MPH

Scott Janiczak, PharmD, MPH

Team Leader, Division of Pharmacovigilance-I, OSE, CDER, FDA, United States

In December 2025, FDA finalized its guidance for industry regarding Sponsor responsibilities for safety reporting requirements and safety assessment for investigational new drug (IND) studies. This guidance provides an overview of the FDA’s IND safety reporting requirements and includes, among other information, recommendations for the development of safety surveillance plans and considerations for aggregate data analyses as required by the IND safety reporting provisions (§§ 312.32(c)(1)(i)(C) or 312.32(c)(1)(iv)). In this session, representatives from FDA will provide an overview of the guidance, highlight key updates and discuss recommendations to help sponsors comply with these requirements. Additionally, representatives from Industry will provide real-world perspectives on translating the guidance into an operational framework for evaluating accumulating safety data across clinical development programs. Attendees will leave with strategies to develop process efficiencies and optimize overall compliance with IND safety reporting requirements.

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Understand FDA expedited safety reporting and updated aggregate analysis approaches
  • Communicate serious safety risks while preserving trial integrity
  • Identify key elements of an aggregate safety surveillance strategy
  • Integrate blinded and unblinded aggregate analyses through independent review

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.